BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Labeur TA, Achterbergh R, Takkenberg B, Van Delden O, Mathôt R, Klümpen HJ. Sorafenib for Patients with Hepatocellular Carcinoma and Child-Pugh B Liver Cirrhosis: Lessons Learned from a Terminated Study. Oncologist 2020;25:e1274-9. [PMID: 31645371 DOI: 10.1634/theoncologist.2019-0718] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Woei-A-Jin FJSH, Weijl NI, Burgmans MC, Fariña Sarasqueta A, van Wezel JT, Wasser MNJM, Coenraad MJ, Burggraaf J, Osanto S. Neoadjuvant Treatment with Angiogenesis-Inhibitor Dovitinib Prior to Local Therapy in Hepatocellular Carcinoma: A Phase II Study. Oncologist 2021. [PMID: 34251745 DOI: 10.1002/onco.13901] [Reference Citation Analysis]
2 Shi J, Ren M, She X, Zhang Z, Zhao Y, Han Y, Lu D, Lyu L. Transgelin-2 contributes to proliferation and progression of hepatocellular carcinoma via regulating Annexin A2. Biochem Biophys Res Commun 2020;523:632-8. [PMID: 31941608 DOI: 10.1016/j.bbrc.2020.01.028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
3 Zhang CH, Li M, Lin YP, Gao Q. Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes. Curr Gene Ther 2020;20:84-99. [PMID: 32600231 DOI: 10.2174/1566523220666200628014530] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Wang T, Chen B, Meng T, Liu Z, Wu W. Identification and immunoprofiling of key prognostic genes in the tumor microenvironment of hepatocellular carcinoma. Bioengineered 2021;12:1555-75. [PMID: 33955820 DOI: 10.1080/21655979.2021.1918538] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
5 Park MK, Lee YB, Moon H, Choi NR, Kim MA, Jang H, Nam JY, Cho EJ, Lee JH, Yu SJ, Kim YJ, Yoon JH. Effectiveness of Lenvatinib Versus Sorafenib for Unresectable Hepatocellular Carcinoma in Patients with Hepatic Decompensation. Dig Dis Sci 2022. [PMID: 35048224 DOI: 10.1007/s10620-021-07365-9] [Reference Citation Analysis]
6 Blanc JF, Khemissa F, Bronowicki JP, Monterymard C, Perarnau JM, Bourgeois V, Obled S, Abdelghani MB, Mabile-Archambeaud I, Faroux R, Seitz JF, Locher C, Senellart H, Villing AL, Audemar F, Costentin C, Deplanque G, Manfredi S, Edeline J; PRODIGE 21 collaborators. Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosis. Hepatol Int 2021;15:93-104. [PMID: 33420951 DOI: 10.1007/s12072-020-10120-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Jia H, Gao Z, Yu F, Guo H, Li B. Actin-binding protein anillin promotes the progression of hepatocellular carcinoma in vitro and in mice. Exp Ther Med 2021;21:454. [PMID: 33747188 DOI: 10.3892/etm.2021.9885] [Reference Citation Analysis]